Mirabegron – USA
On Sep. 18, 2024, Federal Circuit vacated District court’s judgment and remanded the case in which district court determined, sua sponte that claims of U.S. Patent 10,842,780 are invalid under 35 U.S.C. § 101.
In Astellas Pharma, Inc. v. Sandoz Inc., Astellas Pharma appealed a decision by the U.S. District Court for the District of Delaware. The court ruled that claims 5, 20, and 25 of Astellas’s U.S. Patent No. 10,842,780 (related to …